NCT07328425 (ISG-TULIPS) is a Phase 2 clinical trial of Lurbinectedin in Desmoplastic Small Round Cell Tumor, sponsored by Italian Sarcoma Group.

Who is sponsoring NCT07328425?

NCT07328425 is sponsored by Italian Sarcoma Group.

What drugs are being tested in NCT07328425?

Interventions in NCT07328425: Lurbinectedin, Irinotecan.

What condition does NCT07328425 study?

NCT07328425 studies Desmoplastic Small Round Cell Tumor.

Is NCT07328425 still recruiting?

NCT07328425 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT07328425: ISG-TULIPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS

Recruiting now Phase 2 Last updated 3 April 2026

What this trial tests

Phase 2 trial testing Lurbinectedin in Desmoplastic Small Round Cell Tumor in 20 participants. Currently enrolling.

Timeline

21 November 2025

Primary endpoint
1 October 2030

1 October 2030

Quick facts

Lead sponsor	Italian Sarcoma Group
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	21 November 2025
Primary completion	1 October 2030
Estimated completion	1 October 2030
Sites	1 location across Italy

Drugs / interventions tested

Lurbinectedin (LURBINECTEDIN) — full drug profile →
Irinotecan (irinotecan) — full drug profile →

Conditions studied

Desmoplastic Small Round Cell Tumor — all drugs for Desmoplastic Small Round Cell Tumor →

Sponsor

Italian Sarcoma Group — full company profile →

Who can join

15 and older, any sex, with Desmoplastic Small Round Cell Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients participating in this study have DSRCT that has spread locally or to other parts of the body and can no longer be surgically removed without causing significant harm. Treatment will continue until the tumor progresses further, severe side effects occur, or either patient or investigator decision. In addition, patients may participate in an optional biological study. The study will analyze the tumor's genes and the molecules related to them. By studying genes and their products, the investigators can better understand the behavior of the tumor and how the body responds to therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lurbinectedin

Trials testing the same drug.

NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
NCT06681220 — Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC · Phase 1, PHASE2 · recruiting
NCT07141771 — An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing · Phase 1, PHASE2 · not yet recruiting
NCT06217536 — Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas · Phase 1, PHASE2 · withdrawn
NCT06496048 — Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC · Phase 3 · recruiting

Other recruiting trials for Desmoplastic Small Round Cell Tumor

Currently open trials in the same condition.

NCT06849986 — IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) · Phase 2 · recruiting
NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
NCT05918640 — Lurbinectedin in FET-Fused Tumors · Phase 1, PHASE2 · recruiting
NCT04897321 — B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) · Phase 1 · recruiting

Other Italian Sarcoma Group trials

Trials by the same sponsor.

NCT07265661 — Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma · NA · not yet recruiting
NCT06375941 — Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars · recruiting
NCT04274023 — Study on TSR-042 in Advanced Clear Cell Sarcoma · Phase 2 · terminated
NCT04383119 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma · Phase 2 · recruiting
NCT04305548 — Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07328425 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Italian Sarcoma Group
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07328425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing